Quick answer: Growth hormone is a 191-residue protein. Secretagogues are smaller peptides studied at two receptors, GHRH and ghrelin, so they are different reagents with different quality questions. A result for one cannot be applied to another. This page is background, not a product listing.
Two different kinds of molecule
Human growth hormone (hGH) is a protein of 191 amino acids, about 22 kilodaltons, made by the pituitary. A growth hormone secretagogue (GHS) is a different thing: a much smaller molecule, usually a peptide of a few to a few dozen residues, that acts on a receptor and is studied for its ability to prompt the release of the body's own hormone. The two names appear together in search results, which leads buyers to assume they are interchangeable. They are not. One is the hormone, and the other is a class of signaling molecules studied for how they act upstream of it.
This guide compares the two groups as research reagents: what they are, how they differ analytically and what a certificate should show. It is background for laboratory research use only. It does not describe a use in people or animals. For pairwise comparisons inside the secretagogue group, see hexarelin vs. ipamorelin and sermorelin vs. ipamorelin.
Two families of secretagogue, two receptors
The literature separates secretagogues into two main families by the receptor they act on. The first family mimics growth hormone-releasing hormone (GHRH) and acts at the GHRH receptor. Sermorelin, tesamorelin and the CJC-1295 analogs belong here. The second family acts at the growth hormone secretagogue receptor, now usually called the ghrelin receptor. It began with the synthetic hexapeptide GHRP-6, described by Bowers and colleagues in 1984, and continued with GHRP-2, hexarelin and ipamorelin.
The receptor itself was cloned by Howard and colleagues in 1996, and its natural ligand was found three years later when Kojima and colleagues isolated ghrelin from the stomach. That timeline is worth knowing: the synthetic compounds were studied for more than a decade before the natural molecule they imitate was identified. Both families are described in more detail in peptide blends and research stacks and in the single-compound guides linked in this article.
Side-by-side comparison
| Item | Growth hormone (hGH) | GHRH-type secretagogue | Ghrelin-receptor secretagogue |
|---|---|---|---|
| Molecule | 191-residue protein, about 22 kDa | Peptide, e.g. sermorelin (29 residues) | Peptide, e.g. ipamorelin (5), hexarelin (6) |
| Acts at | Growth hormone receptor | GHRH receptor | Growth hormone secretagogue (ghrelin) receptor |
| Role in studies | The hormone being measured | Studied as a prompt for release | Studied as a prompt for release |
| First reported | Purified in the 1950s | GHRH-based analogs, 1980s onward | GHRP-6, 1984; receptor cloned 1996 |
| Main analytical concern | Folding, aggregation, host-cell residue | Truncations, oxidation | Truncations, identity among similar peptides |
| Sold by V8 | No | Sermorelin, tesamorelin, CJC-1295 no-DAC | Ipamorelin, hexarelin |
How the research reagents differ from hGH
The first difference is size. A secretagogue such as ipamorelin has five residues, hexarelin six and sermorelin 29, while hGH has 191 and a defined folded structure held by two disulfide bridges. Small linear peptides are made by solid-phase synthesis. A 191-residue protein is normally made in expression systems, and its quality questions are different: aggregation, folding, glycan-free identity and residual host-cell material rather than truncated chains.
The second is the target. A secretagogue is studied as a ligand for a receptor on pituitary and hypothalamic cells, so the result in an assay depends on the receptor and the model, while hGH is studied as an effector acting on its own receptors. The third is the readout. Work on secretagogues measures hormone release or receptor signaling; work on hGH measures the effects of the hormone. Putting results from one onto the other is a category error, which is the main reason this comparison is worth writing down.
Within the secretagogue group
Selectivity is one of the dimensions where the group varies. Raun and colleagues described ipamorelin in 1998 as a selective secretagogue in animal and cell models, reporting that it released growth hormone without the rise in other pituitary hormones that earlier compounds in the class showed in those models. Hexarelin and GHRP-6 were reported with broader effects in the same period of research. The long-acting GHRH analog CJC-1295 was described by Teichman and colleagues in 2006 in a human pharmacology study, which is useful to know as a source of data on how a modified analog differs from the native sequence.
A review by Sigalos and Pastuszak (2018) collects the clinical and preclinical literature on the group and is a sound place to start. For a reader who works with these molecules in the laboratory, the practical point is that each one has its own sequence, mass, handling properties and published model, so a result for one compound is not a result for another.
Comparison table
The side-by-side table earlier in this article gives the research-level facts. Masses are approximate and come from the published sequences.
What a certificate should show
For the small peptides the key items are the sequence or name of the exact compound, a measured mass next to the expected mass, purity by HPLC, the lot and the date. A purity percentage without an identity result cannot distinguish one secretagogue from another, and several of them have similar retention behavior. For background on reading these documents, see understanding HPLC purity, HPLC vs. mass spectrometry and how to read a COA.
For a protein such as hGH the list is longer and includes methods for aggregation and identity that are outside what V8 offers, since V8 does not sell hGH. For any compound intended for cell work, endotoxin and sterility results matter as much as purity. Buyer-side guidance is in choosing a peptide supplier and red flags when buying research peptides.
Handling and record keeping
Keep lyophilized peptide cold, dry and dark, and write the date on a vial when it is first opened. Limits on solution storage are in how long reconstituted peptides last, and ordinary appearance is in what a normal vial looks like. Record the compound, sequence, lot, supplier, certificate date and storage conditions in the notebook, so a later reader can tie a result to a defined reagent rather than to a class name.
Frequently asked questions
Is a growth hormone secretagogue the same as growth hormone?
No. Growth hormone is a 191-residue protein. A secretagogue is a smaller molecule studied for its ability to act at a receptor that is involved in release of the hormone.
What are the two main secretagogue families?
One acts at the GHRH receptor (sermorelin, tesamorelin, CJC-1295 analogs). The other acts at the ghrelin receptor (GHRP-6, GHRP-2, hexarelin, ipamorelin).
Who identified the ghrelin receptor and its natural ligand?
Howard and colleagues cloned the receptor in 1996, and Kojima and colleagues isolated ghrelin in 1999.
Why can't results for one secretagogue be applied to another?
Each has its own sequence, mass, receptor behavior and published model, so a result belongs to the compound and conditions it was measured in.
How does the size of the molecules differ?
Ipamorelin has five residues, hexarelin six and sermorelin 29, while hGH has 191 and a folded structure.
Why is ipamorelin called selective in the literature?
Raun and colleagues reported in 1998 that it released growth hormone in their models without the rise in other pituitary hormones seen with earlier compounds.
Does V8 sell growth hormone?
No. V8 lists some research secretagogue peptides; this page is background and not a product listing.
What should a COA show for a secretagogue?
The exact compound, a measured mass beside the expected mass, HPLC purity, lot and date. Purity alone does not prove identity.
Does this article describe a use in people?
No. It summarizes published laboratory research and analytical practice. Nothing here is a recommendation for use in people or animals.
What should I record for each vial of any research peptide?
The exact compound name, sequence, lot identifier, certificate date, supplier, storage conditions and the date the vial was opened.
References
- Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53.
